In contrast, activation of the PI3K pathway is suggested to cause endocrine resistance in ER-positive advanced breast cancer, and therefore inhibitors for PI3K, AKT, and mTOR have potential therapeutic utility in patients with this tumor subtype12,13. Here, AKT1 is linked to neoplasm.